STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

Blood

Volumn 120, Issue 15, 2012, Pages 3048-3057

  Jerez, Andres ^a   Clemente, Michael J ^a   Makishima, Hideki ^a   Koskela, Hanna ^b   LeBlanc, Francis ^c   Ng, Kwok Peng ^a   Olson, Thomas ^c   Przychodzen, Bartlomiej ^a   Afable, Manuel ^a   Gomez Segui, Ines ^a   Guinta, Kathryn ^a   Durkin, Lisa ^d   Hsi, Eric D ^d   McGraw, Kathy ^e   Zhang, Dan ^c   Wlodarski, Marcin W ^f   Porkka, Kimmo ^b   Sekeres, Mikkael A ^a   List, Alan ^e   Mustjoki, Satu ^b   Loughran, Thomas P ^c   Maciejewski, Jaroslaw P ^a   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Division of Hematology   (Finland)

^c PENN STATE CANCER INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; STAT3 PROTEIN; STAT3 PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL EXPANSION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXON; FEMALE; GENE ACTIVATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SRC HOMOLOGY DOMAIN; T LYMPHOCYTE; WILD TYPE;

EID: 84867815120     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-435297     Document Type: Article

References (38)

1. Loughran TP Jr, Kadin ME, Starkebaum G, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102(2):169-175. (Pubitemid 15157163)
2. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.
3. Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Ed). Lyon, France: International Agency for Research on Cancer; 2008.
4. Swerdlow SH, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Ed). Lyon, France: International Agency for Research on Cancer; 2008.
5. Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534-1541.
6. Epling-Burnette PK, Sokol L, Chen X, et al. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008;112(12):4694-4698.
7. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy."J Exp Med. 1994;179(2):609-618.
8. Bigouret V, Hoffmann T, Arlettaz L, et al. Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors. Blood. 2003;101(8):3198-3204. (Pubitemid 36858015)
9. Ryan DK, Alexander HD, Morris TC. Routine diagnosis of large granular lymphocytic leukaemia by Southern blot and polymerase chain reaction analysis of clonal T cell receptor gene rearrangement. Mol Pathol. 1997;50(2):77-81. (Pubitemid 27455007)
10. Zambello R, Falco M, Della Chiesa M, et al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood. 2003;102(5):1797-1805. (Pubitemid 37022576)
11. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-1913.
12. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89(1):256-260. (Pubitemid 26428200)
13. Mohan SR, Clemente MJ, Afable M, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica. 2009;94(10):1407-1414.
14. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425. (Pubitemid 44061337)
15. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001;98(1):165-173.
16. Morice WG, Kimlinger T, Katzmann JA, et al. Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. Am J Clin Pathol. 2004;121(3):373-383. (Pubitemid 38298171)
17. O'Keefe CL, Plasilova M, Wlodarski M, et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol. 2004;172(3):1960-1969. (Pubitemid 38116847)
18. ZengW, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood. 2006;107(1):167-175. (Pubitemid 43053539)
19. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82(2):241-250.
20. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798-809.
21. Song H, Wang R, Wang S, Lin J. A low-molecularweight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A. 2005;102(13):4700-4705. (Pubitemid 40471517)
22. Zambello R, Trentin L, Ciccone E, et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood. 1993;81(9):2381-2385. (Pubitemid 23127074)
23. Epling-Burnette PK, Painter JS, Chaurasia P, et al. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood. 2004;103(9):3431-3439. (Pubitemid 38525675)
24. Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118(16):4384-4393.
25. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell. 2008;13(1):7-9. (Pubitemid 350309747)
26. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003;63(11):2948-2956. (Pubitemid 36667168)
27. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growthsuppression activity. Nat Genet. 2001;28(1):29-35. (Pubitemid 32405812)
28. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362.
29. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608-1619. (Pubitemid 47598403)
30. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448(7157):1058-1062. (Pubitemid 47345590)
31. Kumanovics A, Perkins SL, Gilbert H, Cessna MH, Augustine NH, Hill HR. Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. J Clin Immunol. 2010;30(6):886-893.
32. Wallet N, Ghez D, Delarue R, et al. Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome. Clin Lymphoma Myeloma. 2007;7(6):425-427. (Pubitemid 47057021)
33. Starkebaum G. Leukemia of large granular lymphocytes and rheumatoid arthritis. Am J Med. 2000;108(9):744-745. (Pubitemid 30621465)
34. Namekawa T, Snyder MR, Yen JH, et al. Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol. 2000;165(2):1138-1145. (Pubitemid 30484786)
35. Gulan G, Ravlic-Gulan J, Strbo N, et al. Systemic and local expression of perforin in lymphocyte subsets in acute and chronic rheumatoid arthritis. J Rheumatol. 2003;30(4):660-670. (Pubitemid 36402756)
36. Korb A, Pavenstadt H, Pap T. Cell death in rheumatoid arthritis. Apoptosis. 2009;14(4):447-454.
37. Kim NH, Lee MY, Park SJ, Choi JS, Oh MK, Kim IS. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology. 2007;122(4):607-614.
38. Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood. 2008;111(2):680-687.